Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 106

Posts Tagged ‘diagnostics’

Personal Genome Diagnostics Inc. announced a strategic collaboration with Mayo Clinic

Posted by fidest press agency su venerdì, 10 gennaio 2020

The two organizations have a shared vision for advancing the capabilities of oncology diagnostics and treatment. This collaboration will combine world-class clinical knowledge and expertise in oncology from Mayo Clinic with leadership in genomic technologies from PGDx to accelerate solutions that deliver on the promise of precision medicine.“We are proud to enter into this strategic collaboration with Mayo Clinic. Their deep knowledge of establishing standards of care in oncology, the complexity and volume of cancer cases they see, and their expertise in the implementation of testing in a real-world setting are second to none,” says Doug Ward, CEO, PGDx. “As we continue our quest to empower the fight against cancer, collaborating with Mayo Clinic will allow us to better assess the impact that our elio liquid biopsy and tissue applications will have on improving clinical insights, and will advance innovations in next-generation sequencing technology.” The shared vision and overall goal for PGDx and Mayo Clinic is to improve patient care by advancing the capabilities of oncology diagnostics testing. With a focus on targetable genomic alterations, this collaboration will take advantage of the clinical and technology expertise of both organizations.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

MX3 Diagnostics Announces Partnership with IRONMAN Oceania Series

Posted by fidest press agency su domenica, 8 settembre 2019

MX3 Diagnostics, the company that created the first saliva-based ‘lab-in-your-hand’ health diagnostics platform, today announced that it has been designated the official hydration diagnostics partner for the IRONMAN Oceania Series. IRONMAN Oceania operates a portfolio of elite endurance races including the iconic IRONMAN triathlon series throughout Australia and New Zealand.The MX3 Hydration Testing System Pro Version uses saliva to measure hydration in seconds, allowing trainers and athletes to assess hydration status anywhere at any time. This innovative approach eliminates the need for blood prick or urine tests, generating actionable results in real-time that are uploaded to the MX3 App and stored in the cloud.By making a hydration test quick and convenient, IRONMAN athletes can track fluctuations in their fluid levels day by day, and over time. Athletes now have direct insight into how their training regimen, environment and lifestyle can impact hydration status and the amount of fluid they need to drink while training and during a competition.Training for and competing in races such as IRONMAN requires both physical and mental commitment. Hydration is a key element to sports performance, as dehydration can lead to fatigue, injury and sickness. MX3 is leveraging the convenience of saliva to test for hydration and empower athletes with real-time visibility into their personalized hydration data. Dave Beeche, the managing director of the Oceania IRONMAN Group, said competing in IRONMAN at all levels is about maximizing performance to help make the impossible a reality.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Global In Vitro Diagnostics (IVD) Market by Product, Technology, Application, and End-use

Posted by fidest press agency su mercoledì, 12 giugno 2019

The global in vitro diagnostics market size is expected to reach USD 100.8 billion by 2026 registering a CAGR of 4.75%, according to this new report.Favorable government regulations supporting approval process of medical devices and rising geriatric population are among the key factors driving the market. For instance, in August 2018, the central government of India amended provisions in the Fourth Schedule of Medical Devices Rule to ease the approval process for IVD devices. In July 2017, bioMerieux received an FDA approval for VITEK MS, its mass spectrometry system for rapid identification of pathogens, such as mycobacteria, molds, and Nocardia species.In addition, various initiatives by private and public organizations are projected to fuel market growth. For instance, In July 2018, NAMSA-a Medical Research Organization-launched its Uniquely IVD development services to expedite the commercialization of IVD devices for global manufacturers. NAMSA is collaborating with global regulatory bodies to investigate the international regulatory framework and delivers highly reliable IVD development outputs related to clinical research initiatives, quality, and regulatory systems.Furthermore, rising need for onsite and early diagnosis and treatment plans is anticipated to accelerate the demand for highly accessible IVD products. Rising prevalence of diseases, such as Cardiovascular Disorders (CVDs), cancer, and diabetes, are also expected to increase the demand for IVD. According to Cancer Research U.K., in 2018, about 17 million cancer cases were reported. Key companies, such as Becton, Dickinson and Company; Hologic, Inc. (Gen-Probe); bioMerieux SA; and F. Hoffmann-La Roche Ltd.; are focusing on product development, collaborations, and M&A to increase their market share and product portfolio.For instance, in February 2018, BD announced the availability of PAXgene Blood ccfDNA tube (CE-IVD marked) used for cancer and non-invasive prenatal testing application in Switzerland and the European Economic Area. This product was developed by a joint venture of BD and Qiagen-PreAnalytiX GmbH. In addition, in September 2018, Cepheid received CE-IVD clearance for Xpert HCV VL Fingerstick used to detect and quantify HCV RNA levels from fingerstick blood sample.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

TTP plc Collaborates with Quotient Ltd to Transform Transfusion Diagnostics and Beyond

Posted by fidest press agency su mercoledì, 22 maggio 2019

TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with Quotient Ltd (NASDAQ:QTNT), a commercial-stage diagnostics company committed to transforming transfusion diagnostics and beyond – to develop and implement a state-of-the-art manufacturing facility for Quotient’s proprietary MosaiQ™ system.MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. The instrument is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements and operational cost savings to laboratories around the world.
TTP has been an integral development partner for MosaiQ, providing extensive technology, science and engineering input to make possible Quotient’s vision to develop a multiplexed testing platform based on a custom consumable, including a microarray, and a custom instrument.
TTP initially undertook a product feasibility study and carried this through to the conception and delivery of a high-volume, consumable-manufacturing facility. This included the design and manufacture of a low-cost consumable, development of robust manufacturing systems, and several bespoke high-volume manufacturing processes, including microarray printing, array processing and high-speed assembly, as well as the use of ‘User Centred Design’ research to specify the user requirements of the processing instruments. Key to the printing of microarrays for this pre-transfusion blood testing, which includes printed blood cells and antibodies, is SureDrop, TTP’s bespoke microarray printing technology that has a unique capability to print a broad range of materials, including cells, proteins, DNA, and polymers. The SureDrop print module forms part of the MosaiQ system. To facilitate Quotient’s requirements, TTP developed a custom-made print module, incorporating improvements to the technology necessary for this application, and a high-volume manufacturing line, operating within its own quality management system, was established at TTP’s Melbourn Science Park headquarters to ensure the successful delivery of production print modules.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

“US In-Vitro Diagnostics Market- Growth, Trends, and Forecast (2019 – 2024)”

Posted by fidest press agency su martedì, 26 marzo 2019

The report has been added to ResearchAndMarkets.com’s offering.The key factors propelling the growth of the market is the high prevalence of chronic diseases, increasing use of POC (Point-of-care) diagnostics, advanced technologies, and increasing awareness and acceptance of personalized medicine. The increasing government healthcare expenditure and consumer’s healthcare spending are also responsible for the growth of the market.The increase in the US in vitro diagnostics market is majorly due to the high prevalence of chronic diseases, such as heart diseases, cancer, asthma, and diabetes. It is estimated that these diseases are responsible for the majority of deaths in the United States, killing more than 1.7 million US citizens annually. Thus, IVDs have proved to be beneficial in managing these chronic conditions. IVDs help in the detection of early warning signs and individual risk factors, creating new opportunities for prevention and early intervention.There are also emerging technological innovations, such as lab-on-a-chip, wearable devices, and POC diagnostics that are increasingly becoming an important part of the healthcare landscape. These POC diagnostic products have been developed to be used on a patient’s bedside in hospitals, to get instant results without the need of sending the samples to the lab. Thus, owing to the ease of use and the ability to provide instant results, the use of POC diagnostics in the United States is increasing rapidly.
As per the scope of the report, in vitro diagnostics are the medical devices and consumables utilized to perform in vitro tests on various biological samples. They are basically used for the diagnosis of various medical conditions. These in vitro diagnostics products can be instruments, reagents, or any system used for the diagnosis of diseases.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Diagnostics Data Analytics Company Diaceutics to List on London Stock Exchange

Posted by fidest press agency su venerdì, 22 marzo 2019

Diaceutics plc, a revenue-generating and profitable diagnostics data analytics and implementation services company which services the global pharmaceutical industry, today announces that it is seeking a listing on the AIM Market of the London Stock Exchange. The company is expected to have a market capitalization on admission of approximately £53M.
Diaceutics has conditionally raised £17M by way of a Placing of 22,368,427 Ordinary Shares of 76p each through its nominated adviser and broker, Cenkos Securities plc. It is expected that Admission will become effective at 8am on or around 21st March 2019 and shares will trade under the AIM symbol ‘DXRX’.Diaceutics was founded in 2005 by Peter Keeling and operates in the global diagnostics commercialization market. With offices in Belfast, UK; Dundalk, Ireland; Parsippany, New Jersey; and Singapore, the organization’s services result in more effective pairing of patients with specific treatments, which in turn leads to better patient healthcare outcomes. In 2018, the Group had an average of 65 full-time employees in 17 countries. The Group has achieved compound annual revenue growth in sales of over 50% in the past two years.Last year, 42% of all FDA drug approvals were for precision medicine therapies, representing 25 approvals in total. Precision medicine drugs are tailored to patients expressing specific molecular or genetic biomarkers, which are identified with a diagnostic test. Ineffective testing, accompanied by persistent challenges throughout the current diagnostic testing market, can therefore significantly reduce access to new, more effective drugs.To address this, Diaceutics has amassed a set of data from more than 2,500 laboratories including 3.5M longitudinal patient records, insurance claims data for 50M patients and 58M testing event data points from 35 countries. As part of this data collection, it has accumulated a global proprietary database of individual laboratories’ capabilities across the industry.Using its expertise and its data set, the Group is able to assist pharmaceutical clients improve the development, and delivery, of diagnostic testing. This is manifested through faster testing, better turnaround times, quicker positive identification and higher number of patients treated.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The First International Diagnostics Partnering Conference

Posted by fidest press agency su venerdì, 22 marzo 2019

Diagnostics is one of the fastest growing medical disciplines. Therefore it has been only a matter of time for a fair to focus exclusively on this important topic: DxPx Conference, which will take place for the first time on November 18, 2019 in Duesseldorf, Germany (Airport Hotel Maritim), is the first international partnering conference focusing exclusively on the diagnostics and research tool industry. The event targets established companies, start-ups and investors and will from now on take place every year on the opening day of MEDICA to also attract Asian and US participants.“New and improved diagnostic methods can help patients avoid those endless medical appointment odysseys. They form the basis for efficient individualized treatments. DxPx Conference honors the growing importance of this discipline by creating a platform for international cooperation”, says Dr. Mirko Stange, CEO of SilverSky LifeScience GmbH, the initator and organizer of DxPx Conference. “We are excited to have Roche Diagnostics, Sonic Healthcare’s Bioscientia, and the Business Intelligence provider Research Analytica as our first strong partners. We are also talking to additional well-known sponsors from China and the U.S. and we are convinced that together with our partners we will make the DxPx premiere a success for all parties involved.”Start-ups can apply for free participation in DxPx and one of 15 DxPx presentation slots for showcasing their ideas and products to the international DxPx audience by submitting a short business plan in the conference’s run-up. DxPx sponsors and selected industry experts will act as the jury for selecting the presenting start-ups on the basis of their applications. Interested companies can upload their business plan at http://www.dxpx-conference.com. “We want to promote intensive dialogue between the industry’s newcomers, established players, and fair visitors, and we are looking forward to receiving widely divers applications”, says Mirko Stange. Dr. Peter Wieloch, Head of Bioscientia’s diagnostics2market outlines: “As Europe’s leading lab diagnostic services provider and part of the Australian Sonic Healthcare Group we constantly evaluate partnering options with new diagnostics providers.” Prof. Dr. Wolfgang Kaminski, CMO of Sonic Healthcare Germany adds: “We are always looking for real medical progress to help us further increase the quality of our lab services. We consider DxPx conference a suitable platform for efficiently exchanging insights on management level.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Two Day Infectious Disease Diagnostics Conference

Posted by fidest press agency su venerdì, 21 dicembre 2018

London, United Kingdom – February 28, 2019 March 1, 2019. The “Infectious Disease Diagnostics Conference” conference has been added to ResearchAndMarkets.com’s offering.According to the World Health Organization, 17 million deaths are caused each year by infectious diseases, accounting for nearly 30% of the annual mortality rate worldwide.
Lower respiratory tract infections, HIV/AIDS, gastro- intestinal diseases, malaria and tuberculosis are together responsible for nearly one-third of all deaths. Various technological developments and advancements in in vitro diagnostics have led to a new variety of diagnostic tests, allowing patients to access novel treatments earlier.
This conference aims to bring different stakeholders together from hospitals, laboratories academic institutes and IVD industry leaders to discuss about the emerging technologies and potential growth of molecular diagnostics and challenges faced in point-of-care testing and antimicrobial resistance. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Siemens Healthineers Announces Acquisition of Fast Track Diagnostics

Posted by fidest press agency su sabato, 16 dicembre 2017

lussemburgoLuxembourg. Siemens Healthineers has signed an agreement to acquire Luxembourg-based Fast Track Diagnostics (FTD), a global supplier of diagnostics tests that, unlike a clinical examination alone, can distinguish between viral, bacterial, or other infections in one test. By introducing FTD products to its molecular diagnostics portfolio, Siemens Healthineers is further investing in precision medicine and better patient experience through solutions that eliminate the need for repeat diagnostic testing, reducing time and improving patient outcomes.The acquisition of FTD increases the menu of the Siemens Healthineers VERSANT® kPCR Molecular System1 by over 80 assays and syndromic panels, transforming care delivery for its customers with a comprehensive solution for molecular testing of infectious diseases. In addition, FTD’s platform-agnostic menu allows Siemens Healthineers to effectively serve a broader customer base.
“By integrating the high-quality and cost effective solutions of Fast Track Diagnostics into our own cutting-edge molecular diagnostics portfolio, Siemens Healthineers continues to strengthen and expand its presence in the field of molecular testing and precision medicine,” says Fernando Beils, Head of Molecular Diagnostics, Siemens Healthineers. “We are excited to introduce both FTD’s products and world-class team to the Siemens Healthineers family.” FTD’s tests are real-time Polymerase Chain Reaction (PCR) kits, allowing for both singleplex and syndromic testing. PCR is a technique used to amplify nucleic acids ( RNA and DNA) in laboratory samples, allowing clinicians to diagnose infections with just a small sample from patients. The tests target conditions such as respiratory infections, gastroenteritis, meningitis, hepatitis, infections of the immunosuppressed, tropical diseases, sexually transmitted diseases, and early childhood diseases, and can detect over 140 viruses, bacteria, parasites, and fungi. By consolidating testing for the infectious disease spectrum into a single molecular ecosystem and virtually open platform, Siemens Healthineers ensures leading-edge performance from extraction through detection, as well as increased workflow efficiency for molecular labs of all sizes.“Combining FTD’s wide range of assays with the Siemens Healthineers portfolio means great things for all of our customers globally,” says Bill Carman, CEO of Fast Track Diagnostics. “In merging our efforts, we’re enabling healthcare providers to meet their current challenges and deliver better outcomes for patients.”“In addressing the evolving needs of our customers and the molecular testing market, we enable them to provide more efficient and more effective care for their patients,” confirms Dr. David Stein, Head of Strategy & Innovation, Siemens Healthineers. “This exciting step forward, alongside our newest team members from FTD, is the latest example of our ongoing commitment to our molecular diagnostics customers and their patients.” Through the acquisition, Siemens Healthineers will now include FTD’s sites in Luxembourg, Malta, and India, as well as its workforce of about 80 employees. FTD will continue to operate under the brand name Fast Track Diagnostics throughout the world.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

SCIEX Announces Joint Venture With Zhenjang Dian Diagnostics in China

Posted by fidest press agency su martedì, 14 novembre 2017

Hangzhou, ChinaHangzhou, China SCIEX Diagnostics, the in vitro diagnostics (IVD) division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced today that it has formed a joint venture (JV) with Zhejiang Dian Diagnostics (Dian), a leader in the research, development and supply of medical diagnostic products and services in China. The parties plan to jointly establish a joint venture in Hangzhou, China to develop, register, manufacture, and commercialize Class I, II and III in vitro diagnostic reagents for the SCIEX Triple Quad™ 4500MD LC-MS/MS system, a solution that was approved by the China Food and Drug Administration (CFDA) earlier this year. Mass spectrometry is known to achieve the high sensitivity, specificity and throughput needed in clinical testing areas such as therapeutic drug measurement, vitamin and steroid hormones, and measurements of inherited metabolic diseases, but the lack of readily available IVD assays has made this technology inaccessible to the majority of hospital labs in China where lab-developed tests (LDT) are limited. By combining SCIEX LC-MS/MS and assay development expertise, with Dian’s laboratory network, cold chain logistics, and China-IVD manufacturing expertise, it is expected that the partnership will accelerate China’s clinical laboratory program and make diagnostic and wellness testing more widespread in the region. As one of the leading diagnostic companies in China, Dian’s diagnostic network stretches to more than 30 laboratories, covering almost all of mainland China, processing more than 100,000 clinical samples per day. To advance clinical diagnostics in China, Dian has also established “precision treatment centers” with high-end “Tier 3” medical institutions, and has a developed a comprehensive service for secondary-level “Tier 2” hospitals and beyond. “Modern-day China contends with many lifestyle factors that can lead to illness. Our aim is to provide wellness testing resources that can help hospitals identify potential health risks before they become chronic,” said Inese Lowenstein, President of SCIEX. “Dian has established many product channels with its wide coverage of high-end medical resources, and this venture will further enrich their existing in vitro diagnostic product lines to enable hospital labs to expand their testing capabilities, and perform tests that they previously were not able to.” “It is an important decision and major breakthrough for Dian to collaborate with SCIEX to promote the industrialization and localization of clinical mass spectrometry,” said Hai bin Chen, Chairman Zhenjang Dian Diagnostics. “This joint venture is the first of its kind in China, and by also working closely with CFDA and Health and Family Planning Commission, we believe it will have a profound influence on the future of wellness and diagnostic testing in China.” A ceremony celebrating the venture will take place at Zhejiang Dian Diagnostics headquarters in Hangzhou, China, on November 11, 2017 attended by SCIEX Senior Leadership Executives.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Edinburgh BioQuarter Announces Launch of i2eye Diagnostics

Posted by fidest press agency su mercoledì, 21 marzo 2012

An aerial view of Edinburgh BioQuarter

An aerial view of Edinburgh BioQuarter (Photo credit: Wikipedia)

Edinburgh, Scotland, (PRNewswire)Edinburgh BioQuarter today announced the launch of i2eye Diagnostics Limited, a company that will deliver the world’s first visual field analyser for patient groups whose visual field was previously impossible to test, including young children and vulnerable adults.i2eye Diagnostics has signed an agreement with the business investment syndicate Kelvin Capital and others for a significant strategic investment which will enable the company to complete the development of its world-first visual field testing instrument.Existing visual field testing instruments depend on the patient’s complete understanding, co-operation and considered feedback and involve keeping the patient’s head still, staring at a fixed point for several minutes. Innovative new technology, known as SVOP (Saccadic Vector Optokinetic Perimetry), harnesses the patient’s natural reactions to movement and light to analyse their visual field without any need for them to keep still, understand the test or give feedback to the tester. Visual field testing can now be performed on very young children as well as many elderly patients and other groups who could not previously be tested. The technology behind the i2eye visual field analyser was developed over five years by a clinical research team at the University of Edinburgh consisting of ophthalmologists, neurologists and medical physicists and led by Robert Minns, Professor of Paediatric Neurology. The new company has been formed with a management team working closely with the Business Creation team at Edinburgh BioQuarter. Peter Estibeiro, i2eye’s Chief Executive Officer, said: “Our instrument is a generation ahead of anything else currently on the market and has enormous potential. One of its first applications is in the monitoring and clinical management of children with brain tumours, where it can aid the decision making process potentially leading to a better outcome. The instrument will be on the market from the middle of 2012 and we are already seeing significant interest from leading paediatric medical centres around the world.” The value of the market targeted by i2eye is estimated at US$280 million in the United States, with markets of similar potential available in Europe and Asia. The company recently returned from exhibiting at the AAO (American Academy of Ophthalmology) Conference in Florida and experienced significant interest from practitioners and distributors spanning the globe.http://www.sdi.co.uk

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Span Diagnostics Ltd. Hits Bull’s eye at ‘ET NOW-IndiaMART

Posted by fidest press agency su domenica, 25 dicembre 2011

The entrance to the iwan of the Jama Masjid, D...

Image via Wikipedia

 What else could have been a better Christmas present for Mr. Veeral Desai, Managing Director, Span Diagnostics Ltd. than a prestigious award at the felicitation ceremony of nation’s most coveted ‘ET NOW-IndiaMART Leaders of Tomorrow Awards 2011′ in Mumbai recently. Mr. NR Narayana Murthy, Chairman Emeritus, Infosys Technologies, presented the award to the winner under Pharmaceuticals & Medical category and appreciated its contribution to fortify the MSME ecosystem with its relentless efforts and creativity. Outlining the importance of MSMEs and these awards, Mr. Dinesh Agarwal, Founder & CEO, IndiaMART.com, said: “These Awards have been governed by the objective of defining leaders in the MSME space and recognising their significance in the Indian economy. We are proud of Span Diagnostics for having emerged a leader of tomorrow and wish them best for robust business growth in future too. Their success would inspire the future MSME leaders and make these awards meaningful.” Joyous after winning this award, Mr. Veeral Desai, Managing Director, Span Diagnostics Ltd., said: “The awards’ importance and value is symbolised by the selection process, and stature of the Jury members. This award has brought sense of pride in each of our employee. It has enhanced our respect and image in society, which we could feel from the stream of messages pouring in from the different sections of society. We will be seen with more esteem by our vendors and customers now. This award has reinforced our faith in management philosophy and practices we follow and given us tremendous strength to pursue our goal with more vigor. It has increased our responsibility and accountability as a corporate citizen too.” Ardently following the founder Dr. Pradip Desai’s ethical business practices and values, Mr. Veeral Desai expects the same from all his employees. He believes in Strategic Management Processes that revolve around the main focus of the company – ‘Innovation and Creativity’. The company develops and manufactures a comprehensive range of indigenous ready-made diagnostic products needed by various segments of healthcare. Presently, it caters to an array of varied sections of diagnostics like Immunology, Biochemistry, Microbiology, Serology, Histopathology and instrumentation. To its humane side, the company does understand that many of the less privileged patients in India do not have access to proper and timely diagnostic solutions. Therefore, it continuously strives to make the company products affordable and improve access to all the needy underprivileged patients, wherever they dwell. Every passing second teaches us something and make us who we are today. This year would be remembered as a phenomenal one for the Indian MSME fraternity, all the winners as well as participants at ‘ET NOW-IndiaMART Leaders of Tomorrow Awards 2011’. It gave them many reasons to believe in hope, many lessons to evolve into a better one and many inspirations to follow.
About Span Diagnostics Ltd. A thought conceived in seventies by a pathologist, Dr. Pradip Desai evolved in to a startup company as Desai Laboratories. The goal was to indigenously develop and manufacture a comprehensive range of ready-made diagnostic products needed by various segments of healthcare. In 1976, Span Diagnostics was formed with an emphasis on in-house R&D to develop more and more products, keeping the customer need in to focus and quality under constant vigil.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »